Combined Therapy of Mosapride and Compound Digestive Enzymes for Functional Dyspepsia

Objective To study the efficacy and safety of combined therapy of mosapride and compound digestive enzymes for functional dyspepsia. Methods Sixty-two patients with functional dyspepsia were randomized into experimental group (n=31) and the controls (n=31) from January 2008 to July 2009. The patients in the control group were only given mosapride 5 mg for 3 times per day, 30 min before meals for 4 weeks. The patients in the experimental group were given 1 capsule of compound digestive enzymes for 3 times per day, 30 min after meals in addition to mosapride for 4 weeks too. The therapeutic efficacy and side effects were compared between the two groups by chi square test. Results The general therapeutic efficacy in the experimental group was superior to the controls (87.1% vs 61.3%, P0.05). The symptoms, such as upper abdominal pain, abdominal distention, early satiety and stomach burn in the patients in the experimental group were more improved than in the control group (P0.05). The experimental group had shown shorter action onset time than the controls. No severe side effects were found in the both groups. Conclusion Combined therapy of mosapride and compound digestive enzymes can more significantly improve general efficacy and symptoms in patients with functional dyspepsia than single use of motility medicine mosapride.